Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Topical calcineurin inhibitors have developed a bad connotation because of a black-box warning that was based on safety concerns of hypothetic systemic absorption and because systemic treatment with calcineurin inhibitors in patients who receive organ transplants is associated with an increased cancer risk. A few case reports of lymphoma and skin cancer in patients treated with topical calcineurin inhibitors initiated the discussion. These drugs were recommended for use as second-line therapy for the short-term and noncontinuous treatment of atopic dermatitis in patients who do not respond adequately to topical corticosteroids or in whom they are contraindicated. According to the latest knowledge, there is no scientific evidence of an increased risk for malignancy due to a topical treatment with calcineurin inhibitors.
Thaçi
Diamant
D
Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D 60590 Frankfurt am Main, Germany. thaci@em.uni-frankfurt.de
Salgo
Rebekka
R
D000287:Administration, Topical; D000818:Animals; D019703:Calcineurin / Q000008:administration & dosage / Q000009:adverse effects*; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008223:Lymphoma / Q000139:chemically induced / Q000517:prevention & control; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D019703:Calcineurin; D016559:Tacrolimus